Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922149 | 0.84 | TNNI3K (0.43) | CYP2C9ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL924261 | 0.84 | SMN1; SMN2 (0.43) | ALDH1A1KMT2ANPC1LMNACA12 | |
| SCHEMBL923317 | 0.81 | EIF2AK2 (0.40) | ALDH1A1KMT2ACA12CA1CA2 | |
| SCHEMBL923227 | 0.78 | AURKA (0.58) | ALDH1A1KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL922373 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KMT2ANPC1LMNACA1 | |
| SCHEMBL7452910 | 0.75 | RAB9A (0.36) | ALDH1A1KMT2ANPC1LMNACA2 | |
| SCHEMBL922369 | 0.74 | KIF11 (0.47) | ALDH1A1KMT2ANPC1LMNACA12 | |
| SCHEMBL922062 | 0.73 | ALDH1A1 (0.46) | ALDH1A1KMT2ALMNACA12CA1 | |
| SCHEMBL11511836 | 0.73 | ALDH1A1 (0.83) | CYP2C9ALDH1A1KMT2ANPC1LMNA | |
| SCHEMBL6949807 | 0.72 | CYP2C9 (0.66) | CYP2C9ALDH1A1KMT2ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | claimed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | claimed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | claimed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | claimed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | CYP2C9 2865/4885ALDH1A1 1614/4885KMT2A 2931/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | CYP2C9 2865/4885ALDH1A1 1614/4885KMT2A 2931/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | CYP2C9 4568/4885ALDH1A1 3393/4885KMT2A 4148/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | CYP2C9 2468/4885ALDH1A1 2487/4885KMT2A 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.